NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Central European Media Enterprises Ltd. (NASDAQ:CETV), Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Nice Ltd. (NASDAQ:NICE), NCS Multistage Holdings, Inc. (NASDAQ:NCSM), NewLink Genetics Corporation (NASDAQ:NLNK), and Colliers International Group Inc. (NASDAQ:CIGI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CETV DOWNLOAD: http://Fundamental-Markets.com/register/?so=CETV
VRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=VRX
NICE DOWNLOAD: http://Fundamental-Markets.com/register/?so=NICE
NCSM DOWNLOAD: http://Fundamental-Markets.com/register/?so=NCSM
NLNK DOWNLOAD: http://Fundamental-Markets.com/register/?so=NLNK
CIGI DOWNLOAD: http://Fundamental-Markets.com/register/?so=CIGI

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Central European Media Enterprises Ltd. (NASDAQ:CETV), Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Nice Ltd. (NASDAQ:NICE), NCS Multistage Holdings, Inc. (NASDAQ:NCSM), NewLink Genetics Corporation (NASDAQ:NLNK), and Colliers International Group Inc. (NASDAQ:CIGI) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed June 1st, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CENTRAL EUROPEAN MEDIA ENTERPRISES LTD. (CETV) REPORT OVERVIEW

Central European Media Enterprises' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Central European Media Enterprises reported revenue of $139.18MM vs $111.73MM (up 24.57%) and basic earnings per share $0.02 vs -$0.09. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Central European Media Enterprises reported revenue of $574.21MM vs $526.17MM (up 9.13%) and basic earnings per share $0.14 vs -$1.28. Central European Media Enterprises is expected to report earnings on July 24th, 2018. The report will be for the fiscal period ending June 30th, 2018.

To read the full Central European Media Enterprises Ltd. (CETV) report, download it here: http://Fundamental-Markets.com/register/?so=CETV

-----------------------------------------

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (VRX) REPORT OVERVIEW

Valeant Pharmaceuticals International's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Valeant Pharmaceuticals International reported revenue of $1,995.00MM vs $2,109.00MM (down 5.41%) and basic earnings per share -$7.68 vs $1.80. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Valeant Pharmaceuticals International reported revenue of $8,724.00MM vs $9,674.00MM (down 9.82%) and basic earnings per share $6.86 vs -$6.94. Valeant Pharmaceuticals International is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $1.05. The estimated EPS forecast for the next fiscal year is $3.54 and is expected to report on February 27th, 2019.

To read the full Valeant Pharmaceuticals International, Inc. (VRX) report, download it here: http://Fundamental-Markets.com/register/?so=VRX

-----------------------------------------

NICE LTD. (NICE) REPORT OVERVIEW

Nice's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Nice reported revenue of $335.44MM vs $305.62MM (up 9.76%) and basic earnings per share $0.39 vs $0.29 (up 34.48%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Nice reported revenue of $1,332.15MM vs $1,015.54MM (up 31.18%) and basic earnings per share $2.37 vs $1.96 (up 20.92%). Nice is expected to report earnings on August 2nd, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $3.22 and is expected to report on February 21st, 2019.

To read the full Nice Ltd. (NICE) report, download it here: http://Fundamental-Markets.com/register/?so=NICE

-----------------------------------------

NCS MULTISTAGE HOLDINGS, INC. (NCSM) REPORT OVERVIEW

NCS Multistage's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, NCS Multistage reported revenue of $70.69MM vs $58.64MM (up 20.55%) and basic earnings per share $0.24 vs $0.18 (up 33.33%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, NCS Multistage reported revenue of $201.63MM vs $98.48MM (up 104.75%) and basic earnings per share $0.05 vs -$0.53. NCS Multistage is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.09. The estimated EPS forecast for the next fiscal year is $1.15 and is expected to report on March 14th, 2019.

To read the full NCS Multistage Holdings, Inc. (NCSM) report, download it here: http://Fundamental-Markets.com/register/?so=NCSM

-----------------------------------------

NEWLINK GENETICS CORPORATION (NLNK) REPORT OVERVIEW

NewLink Genetics' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, NewLink Genetics reported revenue of $9.90MM vs $2.76MM (up 258.57%) and basic earnings per share -$0.49 vs -$0.72. For the twelve months ended December 31st, 2017 vs December 31st, 2016, NewLink Genetics reported revenue of $28.71MM vs $35.77MM (down 19.73%) and basic earnings per share -$2.30 vs -$2.94. NewLink Genetics is expected to report earnings on July 27th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.57. The estimated EPS forecast for the next fiscal year is -$1.75 and is expected to report on March 7th, 2019.

To read the full NewLink Genetics Corporation (NLNK) report, download it here: http://Fundamental-Markets.com/register/?so=NLNK

-----------------------------------------

COLLIERS INTERNATIONAL GROUP INC. (CIGI) REPORT OVERVIEW

Colliers International Group's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Colliers International Group reported revenue of $552.47MM vs $466.26MM (up 18.49%) and basic earnings per share $0.13 vs $0.04 (up 225.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Colliers International Group reported revenue of $2,275.36MM vs $1,896.72MM (up 19.96%) and basic earnings per share $1.27 vs $1.76 (down 27.84%). Colliers International Group is expected to report earnings on August 7th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.73. The estimated EPS forecast for the next fiscal year is $2.46 and is expected to report on February 13th, 2019.

To read the full Colliers International Group Inc. (CIGI) report, download it here: http://Fundamental-Markets.com/register/?so=CIGI

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.